Genomic architecture of autism spectrum disorder in Qatar: The BARAKA-Qatar Study
Mona Abdi,Elbay Aliyev,Brett Trost,Muhammad Kohailan,Waleed Aamer,Najeeb Syed,Rulan Shaath,Geethanjali Devadoss Gandhi,Worrawat Engchuan,Jennifer Howe,Bhooma Thiruvahindrapuram,Melissa Geng,Joe Whitney,Amira Syed,Jyothi Lakshmi,Sura Hussein,Najwa Albashir,Amal Hussein,Ilaria Poggiolini,Saba F Elhag,Sasirekha Palaniswamy,Marios Kambouris,Maria de Fatima Janjua,Mohamed O El Tahir,Ahsan Nazeer,Durre Shahwar,Muhammad Waqar Azeem,Younes Mokrab,Nazim Abdel Aati,Ammira Akil,Stephen W Scherer,Madeeha Kamal,Khalid A Fakhro
DOI: https://doi.org/10.1186/s13073-023-01228-w
2023-10-07
Abstract:Background: Autism spectrum disorder (ASD) is a neurodevelopmental condition characterized by impaired social and communication skills, restricted interests, and repetitive behaviors. The prevalence of ASD among children in Qatar was recently estimated to be 1.1%, though the genetic architecture underlying ASD both in Qatar and the greater Middle East has been largely unexplored. Here, we describe the first genomic data release from the BARAKA-Qatar Study-a nationwide program building a broadly consented biorepository of individuals with ASD and their families available for sample and data sharing and multi-omics research. Methods: In this first release, we present a comprehensive analysis of whole-genome sequencing (WGS) data of the first 100 families (372 individuals), investigating the genetic architecture, including single-nucleotide variants (SNVs), copy number variants (CNVs), tandem repeat expansions (TREs), as well as mitochondrial DNA variants (mtDNA) segregating with ASD in local families. Results: Overall, we identify potentially pathogenic variants in known genes or regions in 27 out of 100 families (27%), of which 11 variants (40.7%) were classified as pathogenic or likely-pathogenic based on American College of Medical Genetics (ACMG) guidelines. Dominant variants, including de novo and inherited, contributed to 15 (55.6%) of these families, consisting of SNVs/indels (66.7%), CNVs (13.3%), TREs (13.3%), and mtDNA variants (6.7%). Moreover, homozygous variants were found in 7 families (25.9%), with a sixfold increase in homozygous burden in consanguineous versus non-consanguineous families (13.6% and 1.8%, respectively). Furthermore, 28 novel ASD candidate genes were identified in 20 families, 23 of which had recurrent hits in MSSNG and SSC cohorts. Conclusions: This study illustrates the value of ASD studies in under-represented populations and the importance of WGS as a comprehensive tool for establishing a molecular diagnosis for families with ASD. Moreover, it uncovers a significant role for recessive variation in ASD architecture in consanguineous settings and provides a unique resource of Middle Eastern genomes for future research to the global ASD community.